

For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Joji Nakayama, Representative Director, President and CEO
(Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Noriaki Ishida, Executive Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126
<http://www.daiichisankyo.com/>

Daiichi Sankyo Launches New Generic Drugs through Its Daiichi Sankyo Espha Subsidiary

Tokyo, Japan (December 8, 2016) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that on December 9, 2016, its generics subsidiary, Daiichi Sankyo Espha Co., Ltd (hereinafter, Daiichi Sankyo Espha), will launch five new generic drugs with three new active ingredients, which have been notified through today’s official gazette.

Overview of Newly Released Products

1. Product Names/Therapeutic Categories


Product name	Therapeutic category	Original brand name
Montelukast Tablets 5mg “DSEP”	Leukotriene receptor antagonist/ Bronchial asthma/allergic rhinitis treatment	Singulair [®] Tablets 5mg, 10mg
Montelukast Tablets 10mg “DSEP”		KIPRES [®] Tablets 5mg, 10mg
Pramipexole Hydrochloride LA Tablets 0.375mgMI “DSEP”	Dopaminergic Parkinson's disease treatment	Mirapex [®] -LA Tablets 0.375mg, 1.5mg
Pramipexole Hydrochloride LA Tablets 1.5mgMI “DSEP”	Sustained-release preparation	
Bosentan Tablets 62.5mg “DSEP”	Endothelin receptor antagonist	Tracleer [®] Tablets 62.5mg

2. Product Attributes

1. Innovative design of PTP Sheets

Ongoing innovations in formulation and labeling reduce the burden on pharmacists when confirming and preventing drug error, and prevent medical error, such as patients taking the wrong medicine or confusing one medicine with another.

- Easily recognizable original symbols
PTP sheets feature original symbols based on formulation and disease characteristics.



- GS1 code on each tablet

GS1 dispenser packaging unit code is displayed on the back of the PTP sheet to reduce the burden on pharmacists in preventing drug error.

GS1 Dispenser Packaging Unit Code

GS1 Code is a barcode in use as a global standard since 2010. One type of GS1 Codes, the GS1 dispenser packaging unit code, offers the advantage of enabling management of product name, volume, content and tablets per sheet.

- Pitch control (fixed position printing)

Makes it easier to identify product name, active ingredient or DSEP display.

- Other innovations

Adopted material that allows content confirmation along with coloring for light shielding for Montelukast Tablets and Pramipexole Hydrochloride LA Tablets.

2. Innovative design of tablets

- Double-sided printing

Product name, active ingredient, etc. are printed on both sides using inkjet, laser or stamp pad printing, according to the characteristics of each method, making print easy to read.

Montelukast Tablets 10mg “DSEP”



*Inkjet double-sided printing
Same design on both sides

Pramipexole Hydrochloride LA Tablets 0.375mgMI “DSEP”



*Laser double-sided printing
Same design on both sides


Bosentan Tablets 62.5mg “DSEP”



*Inkjet double-sided printing
Same design on both sides

Adopts easy-to-split half dose tablets and direction control to prevent printing on dividing lines

Pramipexole Hydrochloride LA Tablets 1.5mgMI “DSEP”



*Stamp double-sided pad printing
Same design on both sides

3. Innovative Box Design

Introducing currently designed boxes (iPackage) for some new products enabling to check the various information when dispensing.


Product Information Card

Detachable product information card (product name, expiration date, etc.) can be used as a product shelf label or to manage remaining sheets

Information Code

Introduced variable information code containing expiration date and serial number data

<Montelukast Tablets 10mg “DSEP” iPackage>



QR Code

Scanning QR code displays the latest package insert

Tablet Image

Allows confirmation of table appearance (both sides) before opening a box

About Daiichi Sankyo Espha

Daiichi Sankyo Espha provides innovative high value-added generic drugs with formulation and devisal labeling as well as authorized generics which are manufactured from the same substances and additives that are manufactured in the same manufacturing methods in the same plant as original drugs based on the spirit of the Daiichi Sankyo Group corporate mission* of supplying pharmaceuticals to address diverse medical needs. Daiichi Sankyo Espha strives to provide pharmaceuticals that provide peace of mind for users by fulfilling the most important pharmaceutical criteria of quality, information, and stable supply while delivering the economic benefits of generics.

*Daiichi Sankyo Group corporate mission: To contribute to the enrichment of quality of life around the world through the creation of innovative pharmaceuticals, and through the provision of pharmaceuticals addressing diverse medical needs.

Daiichi Sankyo Espha Company Overview

Company name: Daiichi Sankyo Espha Co., Ltd.

Established: April 1, 2010

Business: Manufacture and sale of pharmaceuticals

Capital: 450 million yen

Representative: President Hiroto Yoshiwaka

Headquarters: 3-5-1, Nihonbashi, Honcho, Chuo-ku, Tokyo